All In Biotech

NDA 019684 · Pfizer

Procardia Xl

Nifedipine · Oral · Dihydropyridine Calcium Channel Blocker

Last checked: Nov 19, 2026Latest source record: Nov 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Sep 6, 1989

Approved uses

1

Original approval plus efficacy supplements

Registered trials

168

39 Phase 3, 11 recruiting

FAERS reports

47,621

36,714 serious, 5,300 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 21, 2026.

INDICATIONS AND USAGE Vasospastic Angina PROCARDIA XL is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA XL may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. Chronic Stable Angina (Classical Effort-Associated Angina) PROCARDIA XL is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict...

Mechanism: Mechanism of Action A) Angina The precise mechanisms by which inhibition of calcium influx relieves angina has not been fully determined, but includes at least the following two mechanisms: 1) Relaxation and Prevention of Coronary Artery Spasm Nifedipine dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with coronary artery spasm and is responsible for the effectiveness of nifedipine in...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 6, 1989 Original approval · Type 3 - New Dosage Form
3 products under this application
  • PROCARDIA XL · NIFEDIPINE 60MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB2
  • PROCARDIA XL · NIFEDIPINE 90MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB2
  • PROCARDIA XL · NIFEDIPINE 30MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Nifedipine" as an intervention, any sponsor and status, largest first.

All 168 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,641
  • dyspnoea2,507
  • fatigue2,421
  • diarrhoea2,388
  • nausea2,320
  • off label use2,171
  • headache2,101
  • dizziness1,846
  • hypertension1,835
  • pain1,739
  • death1,565
  • asthenia1,539

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004951
20051,016
20061,021
2007777
2008937
20091,038
20101,287
20111,445
20121,576
20131,306
20141,727
20152,093
20162,537
20172,782
20183,241
20193,663
20203,286
20213,017
20222,926
20232,986
20243,075
20252,834
20262,094

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Procardia XL (Nifedipine)

2024 spending

$979K

Beneficiaries

396

1,214 claims

Per beneficiary

$2,471

$10.22 per unit

View as table
YearSpending
2020$2,984,239
2021$2,627,377
2022$2,203,078
2023$2,006,051
2024$978,592

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,481 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.